Encyclopedia of Cancer

Living Edition
| Editors: Manfred Schwab


  • Michiko Yamamoto
  • Noriyuki Masuda
  • Tomoya Fukui
Living reference work entry
DOI: https://doi.org/10.1007/978-3-642-27841-9_249-2



The anthracyclines that have been tested clinically so far have been limited to those produced by fermentation or semi-synthetic processes. In contrast, 9-aminoanthracycline oramrubicin is a fully synthetic drug. Amrubicin differs from daunosamine in that it contains a 9-amino group and a simple sugar moiety (Fig. 1).


Febrile Neutropenia Maximum Tolerate Dose Overall Response Rate Sensitive Group SCLC Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.


  1. Ding Qand Zhan J (2013) Amrubicin: potential in combination with cisplatin or carboplatin to treat small-cell lung cancer. Drug Des Devel Ther 7:681–689CrossRefGoogle Scholar
  2. Ettinger DS, Jotte R, Lorigan P et al (2010) Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer. J Clin Oncol 28:2598–2603CrossRefPubMedGoogle Scholar
  3. Inoue A, Sugawara S, Yamazaki K et al (2008) Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402. J Clin Oncol 26:5401–5406CrossRefPubMedGoogle Scholar
  4. Inoue A, Ishimoto O, Fukumoto S et al (2010) A phase II study of amrubicin combined with carboplatin for elderly patients with small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0405. Ann Oncol 21:800–803CrossRefPubMedGoogle Scholar
  5. Jotte R, Conkling P, Reynolds C et al (2010) Randomized phase II trial of single-agent amrubicin or topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first-line platinum-based chemotherapy. J Clin Oncol 29:287–293CrossRefPubMedGoogle Scholar
  6. Murakamia H, Yamamotoa N, Shibata T et al (2014) A single-arm confirmatory study of amrubicin therapy in patients with refractory small-cell lung cancer: Japan Clinical Oncology Group Study (JCOG0901). Lung Cancer 84:67–72CrossRefGoogle Scholar
  7. O’Brien ME, Konopa K, Lorigan P et al (2011) Randomised phase II study of amrubicin as single agent or in combination with cisplatin versus cisplatin etoposide as first-line treatment in patients with extensive stage small cell lung cancer – EORTC 08062. Eur J Cancer 47:2322–2330CrossRefPubMedGoogle Scholar
  8. Satouchi M, Kotani Y, Shibata T et al (2014) Phase III study comparing amrubicin plus cisplatin with irinotecan plus cisplatin in the treatment of extensive-disease small-cell lung cancer: JCOG 0509. J Clin Oncol 32:1262–1268CrossRefPubMedGoogle Scholar
  9. Sawa T, Yana T, Takada M et al (2006) Multicenter phase II study of amrubicin, 9-amino-anthracycline, in patients with advanced non-small-cell lung cancer (Study 1): West Japan Thoracic Oncology Group (WJTOG) trial. Invest New Drugs 24:151–158CrossRefPubMedGoogle Scholar
  10. Yanaihara T, Yokoba M, Onoda S et al (2007) Phase I and pharmacologic study of irinotecan and amrubicin in advanced non-small cell lung cancer. Cancer Chemother Pharmacol 59:419–427CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Michiko Yamamoto
    • 1
  • Noriyuki Masuda
    • 1
  • Tomoya Fukui
    • 1
  1. 1.Department of Respiratory MedicineKitasato University School of MedicineSagamiharaJapan